FDA Proposes New System for Customised Drugs to Treat Rare Diseases
Federal health officials have unveiled a groundbreaking proposal aimed at accelerating the development of customised medical treatments for patients suffering from rare or hard-to-treat diseases. The Food and Drug Administration's preliminary guidelines, announced on Monday, would establish a novel regulatory pathway specifically designed for bespoke therapies that have only been tested in a limited number of patients.
Addressing Unmet Medical Needs
The initiative targets conditions that have long been neglected by the pharmaceutical industry due to their limited profitability, particularly rare genetic disorders. FDA Commissioner Marty Makary emphasised the agency's commitment to removing barriers and exercising regulatory flexibility to encourage scientific advances. "It is our priority to deliver more cures and meaningful treatments for patients suffering from rare diseases," Makary stated in an official release.
This announcement follows closely on the heels of another significant FDA policy shift, where the agency indicated it would abandon its decades-old requirement for two clinical trials in standard drug reviews. These recent changes represent a series of adjustments to FDA norms and standards, many of which have bypassed traditional federal rule-making procedures.
New Regulatory Pathway
The proposed system, referred to as the "plausible mechanism" pathway, would create a standardised process for authorising experimental treatments while allowing companies the possibility of commercialising them. This marks a substantial departure from the current "compassionate use" framework, which permits experimental drug use for patients with no alternatives but strictly prohibits profit-making from unapproved treatments.
Under the new approach, FDA regulators would require evidence of a plausible mechanism before greenlighting any experimental therapies. This means treatments must target conditions that are well understood scientifically, with a reasonable expectation that the therapy will act on the underlying genetic or cellular biology of the disease. Researchers must also demonstrate that the therapy successfully targeted the patient's specific genetic or biological abnormality.
Technological Advances Driving Change
The FDA announcement specifically mentions gene editing technologies, although agency officials noted the new approach could apply to various drugs and therapies. In recent years, academic researchers have demonstrated remarkable progress using emerging technologies to correct individual defects in patients' genetic codes.
A notable example from last year involved a team at Children's Hospital of Philadelphia and the University of Pennsylvania, who designed a therapy using CRISPR—the Nobel Prize-winning gene editing tool—to treat a baby born with a rare disease causing dangerous ammonia buildup in the blood.
Overcoming Traditional Barriers
Traditionally, the FDA has required drugmakers to demonstrate safety and effectiveness through clinical studies comparing patients receiving the therapy with control groups. The strength of evidence typically correlates with the number of patients enrolled. However, for conditions affecting only a tiny fraction of the global population, pharmaceutical companies often lack financial incentive to invest the millions of dollars required for comprehensive studies and the lengthy FDA approval process, which can span a decade or more.
Senior FDA officials have clarified that these recent changes, including Monday's proposed pathway, do not constitute new FDA standards. The agency will accept public comments on its draft guidance for 60 days before beginning the finalisation process.
This regulatory shift has been long sought by patients, advocates, and researchers focused on rare diseases, which frequently fall outside both the pharmaceutical industry's conventional business model and the FDA's traditional drug-approval framework. The proposed system represents a significant step toward making personalised medicine more accessible for those with conditions that have historically been overlooked.
